Dyslipidaemia – monotherapy or combined treatment?

Marlena Broncel

eISSN: 2450-4459
ISSN: 2450-3517

Lekarz POZ

Current issue Archive Manuscripts accepted About the journal Supplements Abstracting and indexing Subscription Contact Instructions for authors

Editorial System

Submit your Manuscript

1/2018
vol. 4

Send email

Copy url:

abstract:

Review paper

Dyslipidaemia – monotherapy or combined treatment?

Marlena Broncel

Online publish date: 2018/03/12

View full text Get citation

Statins are the basis of lipid-lowering therapy. When using the most potent atorvastatin or rosuvastatin, LDL-C can be reduced by up to 60%. In clinical practice, not all patients achieve the target LDL cholesterol, especially those with familial hypercholesterolaemia, statin intolerance, or those at very high cardiovascular risk. These patients should be considered for combination treatment. The new PCS K9 drug inhibitors are a very promising form of lipid-lowering therapy. In patients with atherogenic dyslipidaemia with TG > 200 mg/dl (2.3 mmol/l) despite statin treatment, fenofibrate may be considered in combination with statins.

keywords:

Dyslipidaemia – monotherapy or combined treatment?

Marlena Broncel

dyslipidaemia, statins, PCSK9 inhibitors, combined therapy